AI Article Synopsis

  • Transmissible spongiform encephalopathies (TSEs) include diseases like BSE and scrapie, diagnosed through characteristic lesions or by detecting abnormal prion proteins in tissues.
  • Correct tissue sampling is vital for accurate test sensitivity, with rapid tests mostly using ELISA or Western blotting for initial detection.
  • Confirmatory testing involves histology, immunohistochemistry, and advanced methods like electron microscopy, while definitive strain characterization often relies on specialized bioassays using transgenic mice.

Article Abstract

Transmissible spongiform encephalopathies (TSEs) in animals include, among others, bovine spongiform encephalopathy (BSE), scrapie, chronic wasting disease, and atypical forms of prion diseases. Diagnosis of TSEs is based on identification of characteristic lesions or on detection of the abnormal prion proteins in tissues, often by use of their partial proteinase K resistance property. Correctly sampling of target tissues is of utmost importance as this has a considerable effect on test sensitivity. Most of the rapid or screening tests are based on ELISA or Western immunoblot (WB) analysis, and many are officially approved. Confirmatory testing is normally performed by use of histologic examination, immunohistochemical analysis, certain WB protocols, or detection of prion fibrils by use of electron microscopy (scrapie-associated fibril). The discriminatory methods for diagnostic use are mostly based on WB technology and provide initial identification of the prion strain, particularly for differentiation of BSE from scrapie in small ruminants. Definitive prion strain characterization is performed by use of bioassays, usually in mice. A burgeoning number of transgenic mice have been developed for TSE studies. Development of new tests with higher sensitivity and of more reliable diagnostic applications for live animals tested for food safety reasons is a rapidly developing field. Ultimately, the choice of a test for TSE diagnosis depends on the rationale for the testing.

Download full-text PDF

Source
http://dx.doi.org/10.1177/104063870501700601DOI Listing

Publication Analysis

Top Keywords

transmissible spongiform
8
spongiform encephalopathies
8
bse scrapie
8
prion strain
8
prion
5
diagnosis transmissible
4
encephalopathies animals
4
animals review
4
review transmissible
4
encephalopathies tses
4

Similar Publications

Prion diseases, or transmissible spongiform encephalopathies (TSEs), are neurodegenerative disorders caused by the accumulation of misfolded conformers (PrP) of the cellular prion protein (PrP). During the pathogenesis, the PrP seeds disseminate in the central nervous system and convert PrP leading to the formation of insoluble assemblies. As for conventional infectious diseases, variations in the clinical manifestation define a specific prion strain which correspond to different PrP structures.

View Article and Find Full Text PDF

Pathological spectrum of sporadic Creutzfeldt-Jakob disease.

Pathology

November 2024

National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Chancellor's Building, University of Edinburgh, Edinburgh BioQuarter, Edinburgh, United Kingdom; Academic Department of Neuropathology, Centre for Clinical Brain Sciences, Chancellor's Building, University of Edinburgh, Edinburgh BioQuarter, Edinburgh, United Kingdom.

Human prion diseases are a rare group of transmissible neurodegenerative conditions which are classified according to their aetiology as sporadic, genetic or acquired forms. Creutzfeldt-Jakob disease (CJD) is the most common form of human prion disease, with the sporadic form accounting for ∼85% of all reported cases. While advances have been made in the development of clinical tools and biomarkers in the diagnosis of prion disease, allowing greater diagnostic certainty for surveillance purposes, definitive diagnosis requires neuropathological examination of the brain at postmortem.

View Article and Find Full Text PDF

This report presents the results of surveillance on transmissible spongiform encephalopathies in cattle, sheep, goats, cervids and other species, and genotyping in sheep and goats, carried out in 2023 by 27 Member States (MS, EU27), the United Kingdom (in respect of Northern Ireland, (XI)) and other eight non-EU reporting countries: Bosnia and Herzegovina, Iceland, Montenegro, North Macedonia, Norway, Serbia, Switzerland (the data reported by Switzerland include those of Liechtenstein) and Türkiye. In total, 948,165 cattle were tested by EU27 and XI (-3%, compared with 2022), with five atypical BSE cases reported (four H-type: two in Spain, one in France and one in Ireland; one L-type in the Netherlands); and 46,096 cattle by eight non-EU reporting countries with two atypical BSE cases reported by Switzerland. Three additional atypical BSE cases were reported by UK (1), USA (1) and Brazil (1).

View Article and Find Full Text PDF

Quantifying the Molecular Properties of the Elk Chronic Wasting Disease Agent with Mass Spectrometry.

Pathogens

November 2024

Virus and Prion Research Unit, National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Ames, IA 50010, USA.

Article Synopsis
  • Chronic wasting disease (CWD) is a prion disease that impacts both wild and farmed elk, where infectious proteins cause normal proteins to misfold.
  • A study used mass spectrometry to analyze prion proteins from elk inoculated with CWD, focusing on various peptides to measure prion quantity and composition.
  • Results indicated differing amounts of prion proteins in the elk's brain tissue and highlighted the presence of methionine oxidation, demonstrating how mass spectrometry can help identify prion strains on a molecular level.
View Article and Find Full Text PDF

Designed Cell-Penetrating Peptide Constructs for Inhibition of Pathogenic Protein Self-Assembly.

Pharmaceutics

November 2024

Biology Program, Division of Science, New York University Abu Dhabi, Saadiyat Island Campus, Abu Dhabi P.O. Box 129188, United Arab Emirates.

Peptides possess a number of pharmacologically desirable properties, including greater chemical diversity than other biomolecule classes and the ability to selectively bind to specific targets with high potency, as well as biocompatibility, biodegradability, and ease and low cost of production. Consequently, there has been considerable interest in developing peptide-based therapeutics, including amyloid inhibitors. However, a major hindrance to the successful therapeutic application of peptides is their poor delivery to target tissues, cells or subcellular organelles.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!